



## NOTICE OF EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)

The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Extraordinary General Meeting ("EGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund, on Thursday 22 January 2026 at 13.00 CET.

### Right to participate and notice of participation

A shareholder who wishes to participate in the EGM must:

- be registered in the share register kept by Euroclear Sweden AB no later than Wednesday 14 January 2026; and
- notify its intention to participate in the EGM no later than Friday 16 January 2026, either by post to "Bolagsstämman", Immunovia AB, Scheelevägen 8, SE-223 63 Lund, Sweden, or via email to [bolagsstamma@immunovia.com](mailto:bolagsstamma@immunovia.com). The notice shall contain name and personal identity number or corporate registration number, address, telephone number, registered shareholding and number of attending assistants, if any (not more than 2).

### Trustee-registered shares

Shareholders who have had their shares registered in the name of a trustee must, in order to be entitled to participate in the EGM, request the trustee to register their shares in their own name with Euroclear Sweden AB (so-called voting rights registration). The trustee must have completed the voting rights registration no later than as of Friday 16 January 2026, which means that shareholders who wish such voting rights registration must inform the trustee of this well in advance of the said date.

### Proxies etc.

Shareholders intending to participate by proxy must issue a written, signed, and dated power of attorney. The validity term of the power of attorney may not be more than one year, unless a longer validity term is specifically stated in the power of attorney (however at the longest five years). If the power of attorney is issued by a legal entity, the representing proxy must also present an up-to-date certificate of registration (Sw. registreringsbevis) or equivalent document for the legal entity. In order to facilitate the entrance at the EGM, a copy of the power of attorney and other authorization documents should preferably be attached to the shareholder's notification to participate in the EGM. A template power of attorney is available at the company's website ([www.immunovia.com](http://www.immunovia.com)) and will be sent by mail to the shareholders who request it and state their address.

## **Proposed agenda**

- O. Opening of the meeting.
  1. Election of a chairman for the meeting.
  2. Preparation and approval of voting list.
  3. Election of one (1) or two (2) persons to approve the minutes.
  4. Determination of whether the meeting has been duly convened.
  5. Approval of the agenda.
  6. Resolution on (A) amendment of the Articles of Association; and (B) reverse share split.
  7. Closing of the meeting.

## **Proposed resolutions**

### **§ 1 Election of a chairman for the meeting**

The board proposes that lawyer Ola Grahn should be elected as chairman for the meeting.

### **§ 6 Resolution on (A) amendment of the Articles of Association; and (B) reverse share split**

The board of directors proposes that the EGM resolves on a consolidation of shares (so-called reverse share split) whereby hundred (100) existing shares are consolidated into one (1) share (1:100) in accordance with B below. The purpose of the reverse share split is to achieve an appropriate number of shares for the company. In order to enable the reverse share split, the board of directors further proposes that the EGM resolves to amend the company's Articles of Association in accordance with A below.

#### **A. Amendment of the Articles of Association**

In order to enable the reverse share split proposed under B below, the board of directors proposes that the EGM resolves to amend the company's Articles of Association, by adopting new limits for the share capital and the number of shares as follows.

### **§ 4 Share capital**

*Current wording*

The share capital shall be not less than SEK 9,000,000 and not more than SEK 36,000,000.

*Proposed wording*

The share capital shall be not less than SEK 19,500,000 and not more than SEK 78,000,000.

### **§ 5 Number of shares**

*Current wording*

The number of shares shall be not less than 300,000,000 and not more than 1,200,000,000.

*Proposed wording*

The number of shares shall be not less than 6,500,000 and not more than 26,000,000.

#### **B. Reverse share split**

The board of directors proposes that the EGM resolves to carry out a reverse share split, in the ratio 1:100, resulting in hundred (100) shares being consolidated into one (1) share.

The reason for the reverse share split is that the company wants to achieve a number of shares that is appropriate for the company.

If a shareholder's holding of shares does not correspond to a full number of new shares, the excess shares will become the property of the company on the record date for the reverse share split. Excess shares will then be sold at the company's expense by Vator Securities AB, whereby the shareholders concerned will receive their share of the sales proceeds.

After completion of the reverse share split, the number of shares in the company will decrease from 672,666,892 to 6,726,668 (rounded downwards). The proposed reverse share split also means that the quota value of the share increases from SEK 0.03 to approximately SEK 3.00.

The board of directors shall be authorized to determine the record date for the reverse share split, which may not, however, be earlier than the date on which the resolution on the reverse share split has been registered with the Swedish Companies Registration Office. Further information on the procedure for the reverse share split will be published in connection with the board of directors' resolution regarding the record date.

The board of directors' proposals under A – B above constitute a combined proposal and shall be made as a joint resolution. For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the EGM.

#### **Information at the EGM**

Shareholders that are present at the EGM have the right to request information at the EGM pursuant to Chapter 7, Section 32 Paragraph 1 of the Swedish Companies Act (2005:551).

#### **Documents**

The complete proposal for resolution and other documents for the EGM (including power of attorney forms) will be kept available at the company and on the company's website ([www.immunovia.com](http://www.immunovia.com)) no later than three weeks prior to the EGM. The documents will be sent upon request to shareholders providing their address to the company and will also be available at the EGM.

#### **Number of shares and votes**

As per the date of this notice, there are a total of 672,666,892 shares in the company, each share representing one vote. The company does not hold any of its own shares.

#### **Processing of personal data**

For information on how your personal data is processed, see the privacy notice available on Euroclear's webpage, [www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf](http://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf).

-----  
Lund in December 2025  
Immunovia AB (publ)  
The Board of Directors

**For further information, please contact**

Jeff Borcharding, CEO

[jeff.borcharding@immunovia.com](mailto:jeff.borcharding@immunovia.com)

**Immunovia in brief**

Immunovia is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit [www.immunovia.com](http://www.immunovia.com).